Solara Active Pharma Q1 FY27 PAT ₹16.3cr, 18-quarter high

Board approves Q1 FY27 financial results

Solara Active Pharma Sciences said its Board of Directors met on July 23, 2026, to review and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q1 FY27). The company also indicated that the press release and earnings presentation for the board meeting were issued under Regulation 30 of the SEBI Listing Regulations. It said these materials would be made available on its website.

The development matters because it gives investors the first official look at how the company has begun FY27, after a period in which profitability improved quarter-on-quarter but the full-year outcome remained weak. Earlier in the news flow, a “raw alert” referenced Q1 FY27 consolidated net profit of ₹16.3 crore. The company’s earnings update issued on July 23, 2026, carries the same PAT figure for the quarter.

Headline Q1 FY27 numbers: revenue, EBITDA and PAT

In its Q1’27 earnings update dated July 23, 2026, Solara reported overall revenue of ₹384.3 crore for Q1 FY27, up 20% year-on-year. The company reported Q1 FY27 EBITDA of ₹63.5 crore, up 10% year-on-year. Profit after tax (PAT) for the quarter was reported at ₹16.3 crore.

Solara stated that this was the highest EBITDA and PAT it has reported over the last eighteen quarters. It also described Q1 FY27 as another quarter of “resilient execution,” and said the results reflected operating performance and continued execution focus.

Base business (ex-Ibuprofen) drives growth

The earnings update separated the performance of the base business (excluding Ibuprofen) from the commodity Ibuprofen segment. For Q1 FY27, base business revenue was reported at ₹307.7 crore, up 24% year-on-year. Base business EBITDA was reported at ₹72.2 crore, up 8% year-on-year.

The company also reported base business gross margins of ₹158.0 crore, up 10% year-on-year. However, it noted that EBITDA was “marginally impacted” by higher input costs. Solara linked those input-cost pressures to ongoing geopolitical developments in West Asia.

Ibuprofen business: revenue present, profitability pressure continues

Solara reported Q1 FY27 Ibuprofen business revenue of ₹76.5 crore. The company said the Ibuprofen business recorded an EBITDA loss of ₹8.7 crore for the quarter.

In the same update, Solara stated that the commodity Ibuprofen business continues to face profitability challenges in a difficult operating environment. It also reported an EBITDA margin of negative 12% for this segment. Separately, it noted the business delivered about 29% gross margins with about negative 11.4% EBITDA in Q1 FY27.

Profitability narrative: sequential improvement vs full-year loss

The company’s recent profitability track record provides important context for the Q1 FY27 print. Solara recorded consolidated net profit of ₹10.5 crore in Q1 FY26 (quarter ended June 30, 2025). It reported consolidated net profit of ₹9.60 crore in Q4 FY26 (quarter ended March 31, 2026), recovering from a net loss of ₹2.10 crore in the same period of the previous year.

Despite the quarterly improvement, Solara posted an overall net loss of ₹7.41 crore for FY26. This compared with a marginal net profit of ₹0.54 crore in the preceding fiscal year.

What the quarterly tables show for FY26 and early FY27 context

The quarterly data in the provided tables places Q1 FY27 in the context of the immediately preceding FY26 run-rate. For the quarter ended June 30, 2025 (Q1 FY26), the company reported net sales of ₹319.15 crore and profit after tax of ₹10.53 crore in one of the listed quarterly tables. The same section also shows that the quarter ended March 31, 2026 recorded net sales of ₹387.29 crore and profit after tax of ₹9.73 crore.

These table extracts also show key cost items such as total expenditure, interest, and depreciation in prior quarters, highlighting that financing and fixed costs are material lines for the business. While Q1 FY27 detailed line items were not fully laid out in the text excerpt, the company’s earnings update provides the overall revenue, EBITDA, and PAT numbers alongside a segment view.

Analyst call scheduled: margins and Ibuprofen dynamics in focus

Management has scheduled an analyst call on July 23, 2026, at 4:00 PM IST. The company indicated the call would elaborate on margins and Ibuprofen business dynamics.

Given the quarter’s segment split, the Q1 FY27 discussion is likely to focus on how base business growth and profitability are balancing the losses in the commodity Ibuprofen business. The update already points to higher input costs linked to West Asia geopolitical developments as a factor, and investors will watch for details on how those costs flowed through margins.

Market snapshot and identifiers

The provided market snapshot lists Solara Active Pharma Sciences Ltd. under NSE ticker SOLARA and BSE code 541540, in the Pharmaceuticals and Drugs sector. The snapshot also shows a share price of ₹585.40, up ₹16.50 (2.90%). It additionally lists EPS (TTM) at -1.5 and sales growth at -0.4%.

These market data points are shown alongside the company’s quarterly and annual tables, and they frame the Q1 FY27 results announcement within the broader market view of recent performance.

Key numbers at a glance

Recent profitability comparison

Why the Q1 FY27 update matters

The Q1 FY27 numbers show a strong start in headline profitability, with Solara reporting PAT of ₹16.3 crore and indicating it is the highest PAT and EBITDA in eighteen quarters. At the same time, the company’s segment disclosure makes it clear that the Ibuprofen business remains a drag on profitability, with an EBITDA loss and negative margins.

The earnings update also highlights how external factors, including higher input costs linked to geopolitical developments in West Asia, can affect margins even when revenues rise. This mix of base-business growth, commodity-segment volatility, and cost pressures is central to how investors will assess sustainability of the quarter’s performance.

Conclusion

Solara Active Pharma’s board approval of Q1 FY27 results on July 23, 2026, was accompanied by an earnings update reporting revenue of ₹384.3 crore, EBITDA of ₹63.5 crore, and PAT of ₹16.3 crore. The company’s base business reported growth and positive EBITDA, while the Ibuprofen segment continued to report losses.

The next near-term event is the management analyst call scheduled for 4:00 PM IST on July 23, 2026, where the company has said it will discuss margins and Ibuprofen business dynamics.